Publication: Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).
Loading...
Institution Authors
Author
Wainberg, Zev A.
Enzinger, Peter C.
Kang, Yoon-Koo
Yamaguchi, Kensei
Qin Shukui, Qin Shukui
Lee, Keun-Wook
Oh, Sang Cheul
Li Jin, Li Jin
TÜRK, HACI MEHMET
Teixeira, Alexandra Carolina
Advisor
Program
Language
Type
Publisher
Journal Title
Journal ISSN
Volume Title
Abstract
Description
Source
Keywords
Keywords
Citation
Wainberg Z. A. , Enzinger P. C. , Kang Y., Yamaguchi K., Qin Shukui Q. S. , Lee K., Oh S. C. , Li Jin L. J. , TÜRK H. M. , Teixeira A. C. , et al., -Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).-, JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.3, 2021